Suggested Remit: To evaluate the benefits and costs of avalglucosidase alfa within its marketing authorisation for treating Pompe disease for national commissioning by NHS England.
 
Status Proposed
Process HST
ID number 3737

Provisional Schedule

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 14 July 2020 - 11 August 2020
Scoping workshop 11 September 2020 (10:00)

Project Team

Project lead Emily Richards

Email enquiries


For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance